Regulation and status of herbal medicine clinical trials in Korea: a narrative review

다국어 초록 (Multilingual Abstract)

Background: Herbal medicine has been used frequently in Korean medicine. We aimed to summarize the relevant regulations for herbal medicine clinical trials and to analyze their current status in the Republic of Korea.
Methods: We searched for legislation to find regulations on herbal medicine clinical trials. Additionally, the websites of the Korean Ministry of Food and Drug Safety (KMFDS) and Clinical Research Information Service (CRIS) were searched to investigate the current status of them.
Results: To conduct herbal medicine clinical trials for new drugs or previously approved drugs outside of indications, investigational new drug (IND) approval should be obtained from the KMFDS. For clinical trials of herbal medicines that have been used for more than 3 years with 200 cases at the clinical trial institution, nonclinical data can be exempted from IND approval. Total 95 and 108 herbal medicine clinical trials from the KMFDS and CRIS websites were analyzed. The number of clinical trials showed an increasing trend each year, as did KMFDS-regulated clinical trials. Recently, three clinical trials targeting new herbal formulations frequently used in Korean medicine institutions have been approved based on relevant regulations.
Conclusion: We confirmed that herbal medicine clinical trials are managed through strict regulations, which can ensure the safe and effective use of herbal medicine. Despite strict regulations, attempts to accumulate evidence through clinical trials for herbal medicine are increasing. High-quality clinical trials should be conducted to develop new drugs that reflect the clinical setting using relevant regulations, evaluate the efficacy and safety of the drugs, and strengthen insurance coverage.

참고문헌 (Reference)

1 주용준, "한약제제 보험급여 확대 및 활성화 방안에 대한 한의사 인식도 조사" 대한예방한의학회 22 (22): 31-44, 2018

2 여민경, "전국 한방의료기관 한의사 대상 만성질환의 변증활용 현황 조사" 대한예방한의학회 21 (21): 23-34, 2017

3 진희정, "네트워크 분석을 통한 국내 변증 연구의 동향" 한국콘텐츠학회 14 (14): 1037-1046, 2014

4 Motoo Y, "Use of Kampo diagnosis in randomized controlled trials of Kampo products in Japan : a systematic review" 9 (9): e104422-, 2014

5 Kim YJ, "Usage and consumption of Korean medicine Report in 2017" National Institute for Korean Medicine Development 2018

6 Watanabe K, "Traditional Japanese Kampo Medicine : Clinical Research between Modernity and Traditional Medicine-The State of Research and Methodological Suggestions for the Future" 2011 : 513842-, 2011

7 Dai L, "Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018 : Recommendations, Explanation and Elaboration(SPIRIT-TCM Extension 2018)" 25 (25): 71-79, 2019

8 "Regulation on Safety of Medicinal Products, etc. Ordinance of the Prime Minister No. 1641"

9 "Regulation on Approval and Notification of Herbal (crude) Medicinal Preparations, Etc. MFDS Notification No. 2019-143"

10 Yeung WF, "Prescription of chinese herbal medicine in Pattern-Based traditional chinese medicine treatment for depression : A systematic review" 2015 : 160189-, 2015

11 2010 Korea Research-based Pharmaceutical Industry Association, "KOREA IND booklet" Korea Research-based Pharmaceutical Industry Association 2011

12 Lee YM, "Introduction to evidence based medicine" 19 (19): 212-219, 2003

13 Guideline center for Korean Medicine, "IND approval Casebook for the Investigator’s Clinical Trials - focusing on herbal medicine used for more than 3years / 200 cases -" Korean Studies Information Co., Ltd 2019

14 "Guideline for Approving Clinical Study Plans on Drugs. MFDS Notification No. 2019-146"

15 US Food Drug Administration, "Guidance for industry: Estimating the maximum safe starting dose in adult healthy volunteer"

16 National Institute of Food and Drug Safety Evaluation, "Global drug development and evaluation trends" National Institute of Food and Drug Safety Evaluation 2012

17 Hye Lin Woo, "Efficacy and safety of herbal medicine (Dangguijagyag-san) for primary dysmenorrhea: study protocol for a randomized, double-blind, placebo-controlled, parallel-group, multi-center trial" 한국한의학연구원 9 (9): 1-8, 2020

18 Witt CM, "Effectiveness guidance document(EGD)for Chinese medicine trials : A consensus document" 15 : 169-, 2014

19 National Institute of Food and Drug Safety Evaluation, "Complementary casebook of investigational new drug application" National Institute of Food and Drug Safety Evaluation 2019

20 Kim HJ, "Clinical approach to the standardization of oriental medical diagnostic pattern identification in stroke patients" 2011 : 2011

21 Cheng CW, "CONSORT extension for chinese herbal medicine formulas 2017 : Recommendations, explanation, and elaboration" 167 (167): 112-121, 2017